β-Lapachone (β-lap), a novel anticancer agent, is
bioactivated by NADP(H):quinone oxidoreductase 1 (NQO1), an enzyme
over-expressed in numerous tumors, including lung, pancreas, breast, and
prostate cancers. Fast renal clearance and methemaglobinemia / hemolytic
side-effects from the clinical formulation (β-lap-hydroxyl
propyl-β-cyclodextrin complex) hindered its clinical translation. Here,
we investigated a dual model pH responsive polymers for β-lap delivery.
Three pH-sensitive linkages, including acylhydrazone, ketal and imine bonds for
β-lap prodrug syntheses result in an aryl imine linkage the most optimal
linkage. The conversion to β-lap was 2.8%, 4.5% and
100% at pH 7.4, 6.5 and 5.0 in 8 h, respectively. β-lap aryl
imine prodrug conjugated ultra pH-sensitive (UPS) polymer reached high
β-lap loading density (8.3%) and exhibited dual-stages
responsiveness to pH variation. In pHs under pHt, at stage I, micelle
immediately dissociation and subsequently entering stage II, micelles start
quickly release β-lap. In vitro release study showed
that the micelles constantly release β-lap (14.9 ± 0.1%)
at pHs above pHt in 72 h, whereas boosted release of β-lap
(79.4 ± 1.2%) at pH 5.0. Micelle intracellular distribution
predominantly in the lysosome organelle guaranteed their pH responsive
dissociation and subsequently β-lap controlled release. The M-P micelles
retained NQO1-dependent cytotoxicity in A549 lung cancer cells, similar to free
drug in both efficacy and mechanism of cell death. The lysosome-oriented
dual-stage ultra pH responsive β-lap prodrug micelles potentially offer
an alternative nanotherapeutic strategy for lung, as well as other NQO1+ cancer
therapies.